CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses.

@article{Biasoli2005CD10AB,
  title={CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses.},
  author={Irene Biasoli and Jos{\'e} Carlos de Morais and Adriana Scheliga and Cristiane Bedran Milito and Simona Romano and Marcelo Geradin Poirot Land and Wolmar Alcantara Pulcheri and Nelson Spector},
  journal={Histopathology},
  year={2005},
  volume={46 3},
  pages={
          328-33
        }
}
AIMS Diffuse large B-cell lymphoma (DLBCL) is characterized by marked biological heterogeneity. The identification of reproducible parameters that can be combined with the International Prognostic Index (IPI) to better predict outcome could lead to the development of effective risk-adaptive strategies. METHODS AND RESULTS Bcl-2 and CD10 expression was determined by immunohistochemistry. The impact of the positivity on survival was evaluated in combination with the IPI in 86 patients with a… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Similar Papers

Loading similar papers…